

**Quality performance once again vs peers**

**BFSI - Banks** ▶ Result Update ▶ **October 27, 2024**

**TARGET PRICE (Rs): 1,450**

**ICICI Bank posted a 3% beat on PAT at Rs117bn and a superior RoA of 2.4% among peers, primarily due to healthy NII and better fees/treasury gains. Defying industry and peer trends, the bank clocked healthy credit growth at 15% YoY/4% QoQ, driven by some pick-up in corporate, business banking, and non-PL retail book. Deposit growth was equally healthy at 16% YoY/5% QoQ, while the bank maintains reasonable LCR at 120%. Amid most peers reporting higher NPAs, ICICIB continues to witness steady improvement in GNPA ratio to ~2%, while sustaining healthy specific PCR at 79%/contingent buffer @1% of loans amid rising stress in unsecured loans across industry. Management has indicated being cautious on unsecured loans (mainly PL), but believes that overall stress levels remain well below tolerable levels. ICICIB remains our preferred pick in the banking space, given its superior returns profile (RoA: >2%), top-management credibility, and strong capital/provision buffers. We retain BUY on ICICIB with TP of Rs1,450, rolling forward on 2.6x Sep-26E ABV (deserving premium over HDFCB @2.3x) and subsidiaries at Rs215/sh.**

<b>ICICI Bank: Financial Snapshot (Standalone)</b>					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Net profit	318,965	408,883	465,663	510,540	570,347
Loan growth (%)	18.7	16.2	14.1	15.1	17.0
NII growth (%)	30.9	19.6	10.7	12.0	14.6
NIM (%)	4.4	4.5	4.3	4.2	4.2
PPOP growth (%)	25.1	18.4	14.8	14.1	17.0
Adj. EPS (Rs)	45.8	58.4	66.2	72.4	80.9
Adj. EPS growth (%)	36.0	27.5	13.4	9.5	11.7
Adj. BV (Rs)	272.3	317.9	376.9	435.3	501.5
Adj. BVPS growth (%)	19.3	16.7	18.6	15.5	15.2
RoA (%)	2.1	2.4	2.3	2.2	2.1
RoE (%)	17.5	18.9	18.1	17.0	16.5
P/E (x)	22.7	17.6	15.5	14.1	12.7
P/ABV (x)	3.8	3.3	2.7	2.4	2.0

Source: Company, Emkay Research

**Better-than-peer growth trajectory**

Defying industry and peer trends, ICICIB reported healthy credit growth at 15% YoY/4% QoQ. This is mainly driven by some pick up in corporate book, BuB book growing at 30% YoY, and retail also growing at a healthy pace – 14.2% YoY, despite conscious slowdown in the PL book. Deposit growth outpaced industry trend as well at 16% YoY/5% QoQ, leading to a decline in LDR at 85% (-50bps). This, coupled with slight moderation in loan yields (as growth in unsecured loans eases and possibly lower penal interest) and rising CoF led to 9 bps QoQ compression in NIM to 4.27%. Going forward, the bank guides to turn cautious on unsecured loans, while continues to inch-up secured loan growth.

**Strong show on asset quality amid deterioration seen across banks**

ICICIB reported a decline in gross slippages at Rs51bn/1.8% of loans from seasonally higher delinquencies in 1Q due to KCC. This, coupled with higher write-offs led to lower GNPA/NNPA ratios at 2%/0.4% of loans, respectively. Management indicated that stress in unsecured loans has increased over the past 3-4 quarters, but is unlikely to surge as it has taken corrective measures with respect to underwriting, customer quality, and other filters. Additionally, the bank sustains high PCR of 79% and contingent provision buffer at Rs131bn/1% of loans, providing comfort amid rising system-level risks. Bank guides for LLP at 0.4-0.5% of loans in FY25E vs 0.1% earlier, as benign asset quality scenario is already behind.


**ICICI Bank remains our preferred pick in the banking sector**

ICICIB remains our preferred pick in the banking space, given its superior returns profile (RoA: >2%), top-management credibility, and strong capital/provision buffers. We retain BUY on ICICIB with TP of Rs1,450, rolling forward on 2.6x Sep-26E ABV (deserving premium over HDFCB @2.3x) and subsidiaries at Rs215/sh. Key risks: Higher middle/senior management attrition leading to business dislocation, and slower-than-expected growth/margin trajectory owing to macro disruptions.

Target Price – 12M	Sep-25
<b>Change in TP (%)</b>	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	15.5
CMP (25-Oct-24) (Rs)	1,255.5

Stock Data	Ticker
52-week High (Rs)	1,362
52-week Low (Rs)	899
Shares outstanding (mn)	7,048.3
Market-cap (Rs bn)	8,849
Market-cap (USD mn)	105,241
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	15
ADTV-3M (Rs mn)	18,210.1
ADTV-3M (USD mn)	216.6
Free float (%)	100.0
Nifty-50	24,181
INR/USD	84.1
<b>Shareholding, Sep-24</b>	
Promoters (%)	-
FPIs/MFs (%)	37.3/35.6

<b>Price Performance</b>			
(%)	1M	3M	12M
Absolute	(5.2)	4.8	37.0
Rel. to Nifty	2.0	5.8	8.4



**Anand Dama**  
 anand.dama@emkayglobal.com  
 +91 22 6624 2480


**Nikhil Vaishnav**  
 nikhil.vaishnav@emkayglobal.com  
 +91 22 6624 2485

**Kunaal N**  
 kunaal.n@emkayglobal.com  
 +91 22 6612 1275

**Marazbaan Dastur**  
 marazbaan.dastur@emkayglobal.com  
 +91 22 6612 1281


# Story in Charts

**Exhibit 1: Credit growth remains healthy vs peers**




Source: Company, Emkay Research

**Exhibit 2: Margin compression led by elevated CoD and some moderation in loan yields**




Source: Company, Emkay Research

**Exhibit 3: CASA ratio remains largely stable QoQ**




Source: Company, Emkay Research

**Exhibit 4: Corporate watch-list remains well in control**




Source: Company, Emkay Research; Note: Bank has reclassified the nos.

**Exhibit 5: Slippages improved QoQ, but remain range bound...**




Source: Company, Emkay Research

**Exhibit 6: ...while higher w-offs led to improvement in NPA ratios**




Source: Company, Emkay Research

**Exhibit 7: Return ratios remain strong, led by healthy core profitability and contained LLP**




Source: Company, Emkay Research

**Exhibit 8: Healthy margins, fees, better cost management, and contained LLP to protect the >2% RoA trajectory**



Source: Company, Emkay Research

**Exhibit 9: The stock is trading at 2.9x its one-year forward P/ABV, adjusted for its subsidiaries' valuation**



Source: Bloomberg, Emkay Research

**Exhibit 10: ICICI Bank – SOTP-based valuation**

	Stake	Value per share (Rs)	Basis of valuation
ICICI Standalone (A)		1,235	2.9x Sept-26E ABV (adj. for investments)
<b>Non-Banking subsidiaries</b>			
ICICI Prudential Life Insurance	53%	89	2x Sept-26E EV
ICICI Lombard General Insurance	51%	64	30x Sept-26E PAT
ICICI Asset Management Company	51%	51	7% of Sept-26E AUM
ICICI Securities	75%	36	15x Sept-26E PER
Other Subsidiaries	100%	27	
<b>Value of Non-Banking business</b>		<b>266</b>	
Value post Holding Co. discount (20%) (B)		<b>215</b>	
<b>Value of the bank (A+B)</b>		<b>1,450</b>	
Current market price		1,256	
Upside		15%	
Contribution of subs to TP		15%	

Source: Emkay Research

**Exhibit 11: Actuals vs Estimates (Q2FY25)**

(Rs mn)	Actuals	Estimates		Variation		Comments
		Emkay	Consensus	Emkay	Consensus	
Net income	272,246	268,977	268,832	1%	1%	Higher other income led to an in-line number
PPOP	167,232	159,427	159,458	5%	5%	In-line net income and muted opex led to a PPOP beat
PAT	117,459	114,320	110,533	3%	6%	PPOP beat partly offset by higher provisions led to a PAT beat

Source: Emkay Research

**Exhibit 12: Quarterly Summary**

(Rs mn)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	YoY (%)	QoQ (%)	FY24	FY25E	YoY (%)
Interest Earned	349,204	366,946	379,484	389,957	405,374	16	4	1,428,909	1,651,189	16
Interest Expenses	166,125	180,160	188,556	194,429	204,894	23	5	685,852	828,722	21
Net Interest Income	183,079	186,786	190,928	195,529	200,480	10	3	743,059	822,467	11
Global NIMs (reported)	4.53	4.43	4.40	4.36	4.27	-26bps	-9bps	4.53	4.33	-20bps
Non-interest Income	57,767	60,971	56,488	70,019	71,767	24	2	229,577	281,668	23
Operating Expenses	98,553	100,520	97,028	105,300	105,015	7	0	391,327	436,613	12
Pre Provisioning Profit	142,293	147,236	150,388	160,248	167,232	18	4	581,309	667,521	15
Provision & Contingencies	5,826	10,494	7,185	13,322	12,331	112	-7	36,430	48,289	33
PBT	136,466	136,743	143,203	146,927	154,901	14	5	544,879	619,233	14
Income Tax Expense (Gain)	33,856	34,027	36,127	36,336	37,442	11	3	135,996	153,570	13
Net Profit/(Loss)	102,610	102,715	107,075	110,591	117,459	14	6	408,883	465,663	14
Gross NPA (%)	2.48	2.30	2.16	2.15	1.97	-51bps	-18bps	2.32	2.02	-24bps
Net NPA (%)	0.43	0.44	0.42	0.43	0.42	-1bps	-1bps	0.45	0.45	0bps
Deposits (Rs bn)	12,947	13,323	14,128	14,261	14,978	16	5	14,128	16,276	15
Net Advances (Rs bn)	11,105	11,538	11,844	12,232	12,772	15	4	11,844	13,512	14

Source: Company, Emkay Research

**Exhibit 13: Revision in estimates**

Y/E Mar (Rs mn)	FY25E			FY26E			FY27E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	1,094,584	1,104,134	0.9%	1,244,076	1,252,861	0.7%	1,450,261	1,451,238	0.1%
PPOP	656,213	667,521	1.7%	748,530	761,651	1.8%	885,244	891,214	0.7%
PAT	463,263	465,663	0.5%	507,960	510,540	0.5%	568,866	570,347	0.3%
EPS (Rs)	65.9	66.2	0.4%	72.2	72.4	0.4%	80.8	80.9	0.1%
BV (Rs)	395.5	395.3	-0.1%	455.7	455.7	0.0%	523.5	523.6	0.0%

Source: Emkay Research

**Exhibit 14: Key Assumptions**

(%)	FY24	FY25E	FY26E	FY27E
Loan Growth	16.2	14.1	15.1	15.1
Deposit Growth	19.6	15.2	16.8	16.8
NIM	4.5	4.3	4.2	4.2
GNPA	2.3	2.0	1.9	1.9
Credit Cost	0.3	0.4	0.6	0.6
Yield on Advances	10.1	10.1	9.9	9.6
Cost of Deposits	4.6	4.8	4.7	4.5

Source: Emkay Research

## Exhibit 15: Key Ratios and Trends

	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
<b>Loans (Rs bn)</b>	<b>9,386</b>	<b>9740</b>	<b>10,196</b>	<b>10,576</b>	<b>11,105</b>	<b>11,538</b>	<b>11,844</b>	<b>12,231</b>	<b>12,772</b>
<b>- growth YoY (%)</b>	<b>22.7</b>	<b>19.7</b>	<b>18.7</b>	<b>18.1</b>	<b>18.3</b>	<b>18.5</b>	<b>16.2</b>	<b>15.7</b>	<b>15.0</b>
<b>Composition (%)</b>									
Corporate- Domestic & others	23	23	22	23	22	22	21	21	21
Overseas	4	4	3	3	3	3	3	3	3
SME/BuB	4	5	16	5	16	5	17	17	18
Retail	69	70	54	71	55	72	56	55	54
Rural	9	9	9	9	8	8	9	6	6
<b>Deposit (Rs bn)</b>	<b>10,900</b>	<b>11,220</b>	<b>11,808</b>	<b>12,387</b>	<b>12,947</b>	<b>13,323</b>	<b>14,128</b>	<b>14,261</b>	<b>14,978</b>
<b>- growth YoY (%)</b>	<b>11.5</b>	<b>10.3</b>	<b>10.9</b>	<b>17.9</b>	<b>18.8</b>	<b>18.7</b>	<b>19.6</b>	<b>15.1</b>	<b>15.7</b>
CASA (%)	46.6	45.3	45.8	43.3	40.8	38.2	42.2	40.9	40.6
CA (%)	13.3	13.0	13.7	13.0	12.0	10.9	13.7	12.3	12.2
SA (%)	33.3	32.4	32.2	30.3	28.8	27.3	28.5	28.6	28.4
<b>Asset Quality/Capital (%)</b>									
GNPA	3.2	3.1	2.8	2.8	2.5	2.3	2.2	2.2	2.0
NNPA	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4
PCR	81.3	82.6	83.5	83.1	83.1	81.3	80.8	80.2	79.0
Slippages (Rs mn)	43,660	57,230	42,970	53,180	46,870	57,140	51,390	59,160	50,730
Slippages	2.3	2.8	2.0	2.4	2.0	2.3	2.0	2.2	1.8
Restructured loans (% of loans)	0.7	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2
CAR	16.9	16.3	18.3	16.7	17.6	16.7	16.3	16.0	15.4
Tier I	16.2	15.5	17.6	16.0	16.9	16.0	15.6	15.2	14.7
<b>ROE Decomposition (%)</b>									
<b>NII</b>	<b>4.1</b>	<b>4.4</b>	<b>4.6</b>	<b>4.5</b>	<b>4.3</b>	<b>4.3</b>	<b>4.2</b>	<b>4.2</b>	<b>4.1</b>
Other Income (Ex Treasury)	1.4	1.3	1.3	1.3	1.4	1.4	1.2	1.4	1.3
Treasury	(0.0)	0.0	(0.0)	0.1	(0.0)	0.0	0.0	0.1	0.1
Opex	2.2	2.2	2.3	2.4	2.3	2.3	2.1	2.2	2.2
<b>PPOP</b>	<b>3.2</b>	<b>3.5</b>	<b>3.6</b>	<b>3.5</b>	<b>3.4</b>	<b>3.4</b>	<b>3.3</b>	<b>3.4</b>	<b>3.5</b>
Provisions	0.5	0.6	0.4	0.3	0.1	0.2	0.2	0.3	0.3
PBT	<b>2.8</b>	<b>2.9</b>	<b>3.1</b>	<b>3.2</b>	<b>3.2</b>	<b>3.1</b>	<b>3.1</b>	<b>3.1</b>	<b>3.2</b>
Tax	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8
ROA	<b>2.1</b>	<b>2.2</b>	<b>2.3</b>	<b>2.4</b>	<b>2.4</b>	<b>2.3</b>	<b>2.3</b>	<b>2.4</b>	<b>2.4</b>
<b>ROE</b>	<b>16.8</b>	<b>17.8</b>	<b>18.6</b>	<b>18.7</b>	<b>19.2</b>	<b>18.6</b>	<b>18.4</b>	<b>18.0</b>	<b>18.3</b>

Source: Company, Emkay Research; Note: The Bank has reclassified its loan composition with The portfolio comprises borrowers with turnover of upto Rs7.5bn and incorporates business banking, SME, mid-corporate, rural business credit and dealer funding portfolios earlier reported separately/ grouped under other portfolios. Accordingly, we have reclassified the loan composition for Q4FY23, Q2FY24, Q4FY24, Q1FY25, and Q2FY25.

## ICICI Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Interest Income	1,092,313	1,428,909	1,651,189	1,851,751	2,097,735
Interest Expense	471,027	685,851	828,722	930,367	1,041,949
<b>Net interest income</b>	<b>621,286</b>	<b>743,059</b>	<b>822,467</b>	<b>921,383</b>	<b>1,055,786</b>
NII growth (%)	30.9	19.6	10.7	12.0	14.6
Other income	198,314	229,577	281,668	331,478	395,452
<b>Total Income</b>	<b>819,600</b>	<b>972,636</b>	<b>1,104,134</b>	<b>1,252,861</b>	<b>1,451,238</b>
Operating expenses	328,732	391,327	436,613	491,210	560,024
<b>PPOP</b>	<b>490,868</b>	<b>581,309</b>	<b>667,521</b>	<b>761,651</b>	<b>891,214</b>
PPOP growth (%)	25.1	18.4	14.8	14.1	17.0
<b>Core PPOP</b>	<b>490,427</b>	<b>573,179</b>	<b>648,405</b>	<b>738,712</b>	<b>865,981</b>
Provisions & contingencies	66,656	36,430	48,289	82,741	132,773
<b>PBT</b>	<b>424,212</b>	<b>544,879</b>	<b>619,233</b>	<b>678,910</b>	<b>758,441</b>
Extraordinary items	0	0	0	0	0
Tax expense	105,247	135,996	153,570	168,370	188,093
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>318,965</b>	<b>408,883</b>	<b>465,663</b>	<b>510,540</b>	<b>570,347</b>
PAT growth (%)	36.7	28.2	13.9	9.6	11.7
<b>Adjusted PAT</b>	<b>318,965</b>	<b>408,883</b>	<b>465,663</b>	<b>510,540</b>	<b>570,347</b>
<b>Diluted EPS (Rs)</b>	<b>45.6</b>	<b>58.2</b>	<b>65.9</b>	<b>72.2</b>	<b>80.6</b>
Diluted EPS growth (%)	36.0	27.5	13.4	9.5	11.7
<b>DPS (Rs)</b>	<b>8.0</b>	<b>10.0</b>	<b>11.0</b>	<b>12.0</b>	<b>13.0</b>
<b>Dividend payout (%)</b>	<b>17.5</b>	<b>17.2</b>	<b>16.6</b>	<b>16.6</b>	<b>16.1</b>
Effective tax rate (%)	24.8	25.0	24.8	24.8	24.8
Net interest margins (%)	4.4	4.5	4.3	4.2	4.2
Cost-income ratio (%)	40.1	40.2	39.5	39.2	38.6
Shares outstanding (mn)	6,983.9	7,023.4	7,047.3	7,047.3	7,047.3

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
<b>Asset quality</b>					
Gross NPLs	299,860.7	273,139.6	277,669.9	305,297.9	355,170.3
Net NPLs	51,500.7	53,778.6	61,087.4	76,324.5	88,792.6
GNPA ratio (%)	2.9	2.3	2.0	1.9	1.9
NNPA ratio (%)	0.5	0.5	0.5	0.5	0.5
Provision coverage (%)	82.8	80.3	78.0	75.0	75.0
Gross slippages	183,093.8	189,987.9	226,514.9	276,279.6	332,482.7
Gross slippage ratio (%)	1.8	1.6	1.7	1.8	1.8
LLP ratio (%)	0.7	(0.1)	0.1	0.4	0.8
NNPA to networth (%)	2.4	2.1	2.0	2.2	2.3
<b>Capital adequacy</b>					
Total CAR (%)	18.3	16.3	16.9	16.7	16.3
Tier-1 (%)	17.6	15.6	16.2	16.1	15.7
CET-1 (%)	17.1	16.1	16.6	16.4	16.0
RWA-to-Total Assets (%)	67.6	73.4	75.0	76.0	77.0
<b>Miscellaneous</b>					
Total income growth (%)	23.0	28.5	16.5	13.0	14.2
Opex growth (%)	23.0	19.0	11.6	12.5	14.0
Core PPOP growth (%)	27.2	16.9	13.1	13.9	17.2
PPOP margin (%)	38.0	35.1	34.5	34.9	35.7
PAT/PPOP (%)	65.0	70.3	69.8	67.0	64.0
LLP-to-Core PPOP (%)	13.6	6.4	7.4	11.2	15.3
Yield on advances (%)	9.0	10.1	10.1	9.9	9.6
Cost of funds (%)	3.8	4.8	5.0	4.9	4.7

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	13,968	14,047	14,095	14,095	14,095
Reserves & surplus	1,993,186	2,369,946	2,799,098	3,221,852	3,697,741
<b>Net worth</b>	<b>2,007,154</b>	<b>2,383,993</b>	<b>2,813,193</b>	<b>3,235,947</b>	<b>3,711,836</b>
Deposits	11,808,407	14,128,250	16,276,333	19,009,435	22,568,954
Borrowings	1,193,255	1,249,677	1,421,795	1,538,959	1,659,483
<b>Interest bearing liab.</b>	<b>13,834,913</b>	<b>16,331,153</b>	<b>18,377,809</b>	<b>21,271,773</b>	<b>24,950,550</b>
<b>Other liabilities &amp; prov.</b>	<b>833,251</b>	<b>953,226</b>	<b>679,681</b>	<b>723,379</b>	<b>722,113</b>
<b>Total liabilities &amp; equity</b>	<b>15,842,066</b>	<b>18,715,146</b>	<b>21,191,001</b>	<b>24,507,720</b>	<b>28,662,385</b>
Net advances	10,196,383	11,844,064	13,511,595	15,558,431	18,204,885
Investments	3,623,297	4,619,422	5,315,361	6,112,109	7,132,496
Cash, other balances	1,194,383	1,399,260	1,415,850	1,746,614	2,059,417
<b>Interest earning assets</b>	<b>15,014,063</b>	<b>17,862,745</b>	<b>20,242,807</b>	<b>23,417,154</b>	<b>27,396,799</b>
Fixed assets	95,998	108,598	116,428	128,071	140,878
Other assets	732,005	743,802	831,767	962,495	1,124,709
<b>Total assets</b>	<b>15,842,067</b>	<b>18,715,146</b>	<b>21,191,001</b>	<b>24,507,720</b>	<b>28,662,385</b>
BVPS (Rs)	277.8	323.6	383.4	443.4	510.9
Adj. BVPS (Rs)	272.3	317.9	376.9	435.3	501.5
Gross advances	10,444,743	12,063,425	13,728,178	15,787,404	18,471,263
Credit to deposit (%)	86.3	83.8	83.0	81.8	80.7
CASA ratio (%)	45.8	42.2	40.3	40.5	40.5
Cost of deposits (%)	3.3	4.5	4.8	4.7	4.7
Loans-to-Assets (%)	64.4	63.3	63.8	63.5	63.5
Net advances growth (%)	18.7	16.2	14.1	15.1	17.0
Deposit growth (%)	10.9	19.6	15.2	16.8	18.7
Book value growth (%)	17.9	16.5	18.5	15.6	15.2

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	22.4	17.6	15.5	14.1	12.7
P/B (x)	3.6	3.1	2.6	2.2	2.0
P/ABV (x)	3.8	3.2	2.7	2.4	2.0
P/PPOP (x)	17.4	14.7	12.9	11.3	9.7
Dividend yield (%)	0.6	0.8	0.9	1.0	1.0
<b>DuPont-RoE split (%)</b>					
NII/avg assets	4.1	4.3	4.1	4.0	4.0
Other income	1.3	1.3	1.4	1.5	1.5
Fee income	1.2	1.2	1.2	1.2	1.3
Opex	2.2	2.3	2.2	2.1	2.1
<b>PPOP</b>	<b>3.3</b>	<b>3.4</b>	<b>3.3</b>	<b>3.3</b>	<b>3.4</b>
Core PPOP	3.3	3.3	3.2	3.2	3.3
Provisions	0.4	0.2	0.2	0.4	0.5
Tax expense	0.7	0.8	0.8	0.7	0.7
<b>RoA (%)</b>	<b>2.1</b>	<b>2.4</b>	<b>2.3</b>	<b>2.2</b>	<b>2.1</b>
Leverage ratio (x)	8.2	8.0	7.8	7.7	7.7
<b>RoE (%)</b>	<b>17.5</b>	<b>18.9</b>	<b>18.1</b>	<b>17.0</b>	<b>16.5</b>
<b>Quarterly data</b>					
Rs mn, Y/E Mar	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25
NII	183,079	186,786	190,928	195,529	200,480
NIM(%)	4.5	4.4	4.4	4.4	4.3
PPOP	142,293	147,236	150,388	160,248	167,232
PAT	102,610	102,715	107,075	110,591	117,459
EPS (Rs)	58.4	58.5	61.0	62.8	66.7


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
06-Sep-24	1,208	1,450	Buy	Anand Dama
27-Jul-24	1,207	1,450	Buy	Anand Dama
28-Apr-24	1,108	1,450	Buy	Anand Dama
22-Jan-24	1,009	1,400	Buy	Anand Dama
30-Nov-23	935	1,375	Buy	Anand Dama
22-Oct-23	933	1,375	Buy	Anand Dama
23-Jul-23	997	1,330	Buy	Anand Dama
13-Jul-23	956	1,250	Buy	Anand Dama
24-Apr-23	905	1,250	Buy	Anand Dama
09-Mar-23	856	1,250	Buy	Anand Dama
22-Jan-23	870	1,250	Buy	Anand Dama
04-Dec-22	931	1,225	Buy	Anand Dama
24-Oct-22	926	1,170	Buy	Anand Dama
24-Jul-22	800	1,025	Buy	Anand Dama
24-Apr-22	748	1,025	Buy	Anand Dama
23-Jan-22	805	1,025	Buy	Anand Dama
04-Dec-21	716	950	Buy	Anand Dama

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.



**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm’s length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative’s may have Financial Interest/proprietary positions in the securities recommended in this report as of October 27, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s may have material conflict of interest in the securities recommended in this report as of October 27, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative’s may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 27, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	<15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India  
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.